BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Sun Pharmaceutical Industries Ltd. delivered a better than expected Q2 FY23 earnings, led by superior execution in the specialty portfolio, U.S. generics (excluding Taro), and the domestic formulation segment; benefits from the production linked incentive scheme; and a favorable currency movement.
As a percentage of sales, research and development spends remain low at 5.3% versus the management's guidance of 6-8% for FY23, further boosting profitability in Q2.
We have raised our FY23/FY24 earnings per share estimate by 7%/5% to factor in:
enhanced traction in the specialty portfolio,
industry outperformance in branded generics of the DF segment and in emerging markets,
reduced R&D spends, and
better operating leverage.
We remain positive on Sun Pharma on the back of an increased prescription base for the specialty portfolio, robust franchise building in branded generics, niche abbreviated new drug application pipeline awaiting approval, and controlled cost.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.